Pascual, Julio
Panni, Tommaso
Dell’Agnello, Grazia
Gonderten, Saygin
Novick, Diego
Evers, Stefan
Funding for this research was provided by:
This work was supported by Eli Lilly and Company.
Article History
Received: 13 April 2023
Accepted: 26 June 2023
First Online: 17 July 2023
Change Date: 20 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s10194-023-01679-x
Declarations
:
: Ethical approval for the study was granted by the hospital Universitario Marqués de Valdecilla (Spain). All survey respondents provided informed consent and all data were anonymised before analysis.
: Not applicable.
: Julio Pascual has participated in Symposia and Advisory Boards of Allergan, Amgen-Novartis, Biohaven, Teva and Lilly. Tommaso Panni, Grazia Dell ‘Agnello, Saygin Gonderten and Diego Novick are employees and minor shareholders of Eli Lilly and Company. Stefan Evers has no competing interests to declare.